12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Empresa Brasileira de Hemoderivados e Biotecnologia (Hemobras), Baxter sales and marketing update

Brazilian state company Hemobras granted Baxter the exclusive right to become Brazil's provider of recombinant factor VIII ( rFVIII) to treat hemophilia A over the next 20 years. Baxter will receive...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >